Heidi S. Phillips

Heidi S. Phillips

Auto-generated profile, based on publicly available information

Heidi S. Phillips

Departments of *Tumor Biology and Angiogenesis

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2006 in Cancer Cell
Verified
Journal Article
Closed access
HPHeidi S. Phillips
Heidi S. Phillips
SKSamir Kharbanda
Samir Kharbanda
RCRuihuan Chen
Ruihuan Chen
WFWilliam F. Forrest
William F. Forrest
RSRobert H. Soriano
Robert H. Soriano
KAKen Aldape
Ken Aldape

1 December 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ALAlbert Lai
Albert Lai
SKSamir Kharbanda
Samir Kharbanda
WPWhitney B. Pope
Whitney B. Pope
ATAnh Tran
Anh Tran
OSOrestes E. Solis
Orestes E. Solis
HPHeidi S. Phillips
Heidi S. Phillips
Purpose: Mutation in isocitrate dehydrogenase 1 (IDH1) at R132 (IDH1R132MUT) is frequent in low-grade diffuse gliomas and, within glioblastoma (GBM), has been proposed as a marker for GBMs that arise by transformation from lower-grade gliomas, regardless of clinical history. To determine how GBMs arising with IDH1R132MUT differ from other GBMs, we undertook a comprehensive comparison of patients presenting clinically with primary GBM as a function of IDH1R132 mutation status. Patients and Methods: In all, 618 treatment-naive primary GBMs and 235 lower-grade diffuse gliomas were sequenced for IDH1R132 and analyzed for demographic, radiographic, anatomic, histologic, genomic, epigenetic, and transcriptional characteristics. Results: Investigation revealed a constellation of features that distinguishes IDH1R132MUT GBMs from other GBMs (including frontal location and lesser extent of contrast enhancement and necrosis), relates them to lower-grade IDH1R132MUT gliomas, and supports the concept that IDH1R132MUT gliomas arise from a neural precursor population that is spatially and temporally restricted in the brain. The observed patterns of DNA sequence, methylation, and copy number alterations support a model of ordered molecular evolution of IDH1R132MUT GBM in which the appearance of mutant IDH1 protein is an initial event, followed by production of p53 mutant protein, and finally by copy number alterations of PTEN and EGFR. Conclusion: Although histologically similar, GBMs arising with and without IDH1R132MUT appear to represent distinct disease entities that arise from separate cell types of origin as the result of largely nonoverlapping sets of molecular events. Optimal clinical management should account for the distinction between these GBM disease subtypes.

27 February 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LSLiliana Soroceanu
Liliana Soroceanu
SKSamir Kharbanda
Samir Kharbanda
RCRuihuan Chen
Ruihuan Chen
RSRobert H. Soriano
Robert H. Soriano
KAKen Aldape
Ken Aldape
HPHeidi S. Phillips
Heidi S. Phillips
Amplification or overexpression of growth factor receptors is a frequent occurrence in malignant gliomas. Using both expression profiling and in situ hybridization, we identified insulin-like growth factor 2 (IGF2) as a marker for a subset of glioblastomas (GBMs) that lack amplification or overexpression of EGF receptor. Among 165 primary high-grade astrocytomas, 13% of grade IV tumors and 2% of grade III tumors expressed IGF2 mRNA levels >50-fold the sample population median. IGF2-overexpressing tumors frequently displayed PTEN loss, were highly proliferative, exhibited strong staining for phospho-Akt, and belonged to a subclass of GBMs characterized by poor survival. Using a serum-free culture system, we discovered that IGF2 can substitute for EGF to support the growth of GBM-derived neurospheres. The growth-promoting effects of IGF2 were mediated by the insulin-like growth factor receptor 1 and phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3), a regulatory subunit of phosphoinositide 3-kinase that shows genomic gains in some highly proliferative GBM cases. PIK3R3 knockdown inhibited IGF2-induced growth of GBM-derived neurospheres. The current results provide evidence that the IGF2–PIK3R3 signaling axis is involved in promoting the growth of a subclass of highly aggressive human GBMs that lack EGF receptor amplification. Our data underscore the importance of the phosphoinositide 3-kinase/Akt pathway for growth of high-grade gliomas and suggest that multiple molecular alterations that activate this signaling cascade may promote tumorigenesis. Further, these findings highlight the parallels between growth factors or receptors that are overexpressed in GBMs and those that support in vitro growth of tumor-derived stem-like cells.

29 April 2004 in Molecular Brain Research
Verified
Journal Article
Closed access
HPHeidi S. Phillips
Heidi S. Phillips
MNMerry Nishimura
Merry Nishimura
MAMark P. Armanini
Mark P. Armanini
KCKaren Chen
Karen Chen
KAKathryn M. Albers
Kathryn M. Albers
BDBrian M. Davis
Brian M. Davis